EMERYVILLE, Calif.--(BUSINESS WIRE)--Ansa Biotechnologies, Inc., a pioneer of next-generation DNA synthesis, today announced the appointment of Jason T. Gammack as its new chief executive officer. Gammack is joining the company as it completes its early access program for complex synthetic genes and gene fragments and prepares for a full commercial service launch. Founding CEO Dan Lin-Arlow, PhD, will remain with the company and transition to a new position as chief scientific officer.
Ansa’s proprietary DNA synthesis platform is based on precise enzymatic reagents that enable ultra-rapid and controlled single-base additions to a DNA molecule. This environmentally friendly method eliminates the need for harsh chemicals. Since it does not damage the growing DNA molecule as it is made, the method allows for the direct and accurate synthesis of sequences that are hundreds, and potentially thousands, of bases long. These molecules streamline the construction of even longer sequences and greatly facilitate the synthesis of complex sequences that can be difficult or even impossible to produce with legacy techniques. Ansa’s unique approach is poised to accelerate innovation across any industry enabled by synthetic DNA, including biologic therapeutics such as antibodies, gene therapies, and cell therapies, as well as the biomanufacturing of chemicals, materials, foods, and biofuels.
“Ansa Biotechnologies has reached an inflection point in our ongoing mission to shape the future of biology,” said Dr. Lin-Arlow. “We are thrilled to welcome Jason to our team at this pivotal time for our business. His visionary leadership and extensive expertise commercializing life sciences tools and services will be instrumental as we launch our first service offering, drive operational excellence, and position the company for long-term success.”
Gammack brings more than 30 years of life sciences industry experience, during which he has developed successful product and customer engagement strategies for some of the field’s preeminent biotechnology brands. Most recently, he co-founded and was CEO of Resolve Biosciences, where he helped launch a groundbreaking multi-analyte, highly multiplex spatial analysis technology. Prior to that, Gammack was the chief commercial officer at Inscripta, where he oversaw sales, marketing, business development, and customer support for the company’s CRISPR-enabled Onyx™ Digital Genome Engineering platform. Before that, he was vice president of the life science business at QIAGEN, where he led the life science portfolio and go-to-market strategy. He also held senior leadership roles at Ingenuity Systems, Sigma-Aldrich, Invitrogen/Life Technologies, Affymetrix, and Promega Corporation.
“Ansa’s novel and powerful DNA synthesis approach will soon redefine the DNA synthesis landscape and open the door to new sustainable solutions across a wide variety of industries,” said Gammack. “I’m looking forward to working with Dan and our talented team of employees, investors, and collaborators as we empower more researchers with the ability to unlock the next wave of scientific breakthroughs.”
Through Ansa’s early access program for synthetic clonal genes and gene fragments, scientists are for the first time able to explore areas that were previously limited because the DNA sequences were too difficult to synthesize. To learn more, visit ansabio.com/early-access.
About Ansa Biotechnologies
Ansa Biotechnologies is building a fast and reliable DNA synthesis service to accelerate synthetic biology research. Our core technology is a novel, enzymatic method that is faster, cleaner, and more accurate than alternative approaches. The company is headquartered in Emeryville, Calif. For more information, visit ansabio.com or follow us on X and LinkedIn.
Ansa Biotechnologies and the Ansa Biotechnologies logo are trademarks of Ansa Biotechnologies, Inc.
